Why Tandem Diabetes Care Stock Sank Today – The Motley Fool

What happened

Shares of Tandem Diabetes Care (NASDAQ:TNDM) closed down 9.9% on Wednesday after sinking as much as 11.9% earlier in the day. There wasn’t any negative news specific to the insulin pump maker. However, healthcare stocks overall took a beating on Wednesday amid increasing concerns about the political climate in Washington D.C., particularly with the Medicare for All plan proposed by presidential candidate Sen. Bernie Sanders (I-VT).

So what

At this point, the sell-off for Tandem appears to be overdone. There’s a long way to go before Medicare for All has any kind of chance of becoming U.S. law.

Stock charts with arrows going down.

Image source: Getty Images.

Even though some surveys indicate public support for Sen. Sanders’ overhauling of the U.S. healthcare system, that support falls off dramatically when respondents learn more about the details of the plan. For example, a Kaiser Family Foundation (KFF) survey conducted earlier this year found that 56% of Americans supported the Medicare for All plan. But when told that such a system could lead to higher taxes, support fell to 37%. And when told that the government-run approach could lead to delays in getting care, only 26% of Americans supported Medicare for All.

It’s also uncertain how Tandem Diabetes Care would be impacted by the healthcare changes being floated around in Washington. Insulin pumps, such as those marketed by Tandem, are must-haves for many diabetic patients. 

Investors should also keep today’s decline in perspective. Tandem stock soared 51% higher in February and is still up 46% year to date despite the recent pullback. 

Now what

The best thing for investors to do now is to focus on Tandem Diabetes Care’s business prospects and not worry too much about politics. The good news is that those prospects continue to look very bright.

However, Tandem’s valuation is steep, with shares trading at more than 17 times sales. Because of the company’s premium price tag, any holes in the road for healthcare stocks overall could translate to craters in the road for Tandem Diabetes Care.

Share:

More Posts

GRTX – Galera Therapeutics Announces Interim Data from Pilot Phase 1/2 Trial of GC4419 in Combination with Stereotactic Body Radiation Therapy Showed Improved Overall Survival in Patients with Locally Advanced Pancreatic Cancer

Initial results from pilot Phase 1/2 clinical trial in patients with locally advanced pancreatic cancer presented during virtual ASTRO Annual MeetingFirst trial to evaluate anti-cancer activity of one of Galera’s dismutase mimetics in combination with SBRTManagement will host a live audio webcast at 4:30 p.m. EDTMALVERN, Pa., Oct. 27, 2020 (GLOBE NEWSWIRE) — Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced interim data from the full patient population (n=42) in its Phase 1/2 clinical trial of avasopasem manganese (GC4419) in combination with stereotactic body radiation therapy (SBRT) in patients with locally advanced pancreatic cancer (LAPC). The data were presented today during the late-breaker special session of the 2020 American Society for Radiation Oncology (ASTRO) virtual Annual Meeting.GC4419 is an investigational, highly selective small molecule superoxide dismutase mimetic designed to rapidly and selectively convert superoxide to hydrogen peroxide and oxygen. The randomized, double-blind, multicenter, placebo-controlled pilot dose escalation Phase 1/2 trial was designed to evaluate the safety and efficacy of GC4419 in combination with SBRT, compared with SBRT and placebo, in patients with LAPC. The trial assessed safety and efficacy of SBRT when combined with GC4419 or placebo. After completion of induction chemotherapy, patients were randomized (1:1) to receive five-fraction SBRT and 90 mg of GC4419 or placebo control by intravenous infusion one hour prior to each SBRT fraction.In the interim analysis of the intent-to-treat population (n=42), median overall survival (OS) had not been reached at the data cutoff (date of August 24, 2020) in the GC4419 arm, compared to 38.7 weeks (HR=0.4; 95% CI: 0.12-1.11; p=0.06) in the placebo arm. Six-to-eight weeks post-SBRT, patients underwent protocol-specified evaluation for resection, and seven underwent resection. Of the patients in the GC4419 arm who were surgically resected (n=5), all achieved clear / negative margins (R0), one achieved pathological complete response (pCR) and four achieved pathological partial response (pPR), compared to one R0 and pPR of the two surgically resected patients in the placebo arm. No statistically significant differences in progression-free survival (PFS) were observed between GC4419 and placebo (HR=0.6; 95% CI: 0.23-1.56; p=0.29). However, patients were censored for PFS at the date of surgical resection or due to short interval follow up. Toxicity was comparable across both treatment arms, with no significant differences in acute (

HYLN – Investors Should Not Buy Hyliion Stock

Hyliion Holdings (NYSE:HYLN) stock has had a difficult launch since it closed its reverse merger with Tortoise Acquisition Corp. Hyliion stock, trading at $22.80 this afternoon, has fallen over 50% since Sept. 28 when it was changing hands for $48. That was the same day that the reverse merger was approved by the shareholders of both companies.

Source: Shutterstock

Since Oct. 14, the day that the merger closed and the trading symbol was changed to HYLN, the stock is down nearly 30%
But to be fair, the stock, which  previously traded under the symbol SHLL, has risen significantly since the deal was announced on June 19. The stock closed on that day at $14.04.
Assessing Hyliion Holdings
Here is where things stand now for Hyliion, which develops electrified powertrain solutions  for Class 8 commercial trucks. Its pro-forma market capitalization is $3.29 billion. This is for a company that has generated pro-forma revenue of about $1 million in 2020. The company expects to sell 20 of its electrified powertrains in 2020.
However, it does have $520 million of cash and no debt on its balance sheet as a result of PIPE investment (private investment in public equities) funds that it received.
On page 28 of the company’s June 19 slide presentation, it  published a forecast through the end of 2024. The forecast includes the number of electrified powertrains it expects to sell, along with estimates of its revenue, costs, and EBITDA (earnings before interest, taxes, depreciation, and amortization).
Hyliion expects to sell 300 electrified powertrains in 2021 and 6,600 in 2022. So the company predicts that its revenue and total number of products sold will surge 22 times in 2022 versus 2021.

Those estimates might be a little hard for some to believe. Most manufacturing companies do not experience massive leaps in production and deliveries like that in just one year.
That could be a key reason why many have been bearish towards Hyliion stock, which has a high valuation. That pessimism could lead to a further drop in the stock price going forward.
Investors are going to very carefully monitor the company’s production in 2021. By Q4 of 2021, if its  production and deliveries are growing at a rate which indicates that it can sell 6,600 products in 2022, the shares might recover.
What To Do With Hyliion Stock
Some analysts are decidedly negative on the stock. For example, Jacob Kilby, writing in Seeking Alpha, contended that the company will not “electrify the global haulage industry.”
He argues that Hyliion is highly dependent on one customer that is also an investor and calls its sales to that entity an intercompany transfer.
Moreover, much of its production is carried out by many subcontractors, third parties, and others. In terms of costs, Hyliion really does not control its supply chain very well.
According to Bloomberg, the fact  that Hyllion stock has made  28-year-old founder Thomas Healy a billionaire  before the firm has generated much revenue shows that the company has “much to prove.” The woes that Nikola Corp (NASDAQ:NKLA) has experienced provides backing for that point.
The article points out that Healy can only sell 10% of his holdings in the next six months and that he must wait at least two years before he can unload most of the rest of his shares.
I suspect that most investors will want to see several quarterly reports from the newly merged company before buying its shares. I do not recommend buying the shares now.
On the date of publication, Mark R. Hake did not have (either directly or indirectly) any positions in any of the securities mentioned in this article.
Mark Hake runs the Total Yield Value Guide which you can review here.

MRTX – Mirati Shares Hit Record High on Cancer Study Results

Promising results from a study of its cancer drug pushed Mirati Therapeutics Inc. (NASDAQ:MRTX) to an all-time high Monday. Shares of the San Diego-based biotech hit more than $210 and are at about $205 on Tuesday. Meanwhile, the stock of rival Amgen Inc. (NASDAQ:AMGN) slid to a four-month low before closing at just under $225.
Mirati and Amgen are in a race to find which of the companies’ drugs work best in treating defects in the gene called KRAS. KRAS mutations are found in many lung, colorectal and pancreatic cancers, and the lack of an approved therapy designed to attack mutant KRAS signaling means tumors positive for the mutation are often difficult to treat, according to an article in Biopharma Dive.

The surge in Mirati shares is tied to data the company released at a cancer therapeutics conference Sunday. It shows that the Mirati drug adagrasib to treat cancer tumors with the mutation outperformed the Amgen treatment sotorasib. Analysts were quick to respond.
“Simply put, Mirati now appears to have the edge with this data set and a planned NDA (New Drug Application) filing in 2021,” Credit Suisse’s Evan Seigerman said in a note to clients. Credit Suisse rates Murati stock Outperform. SVB Leerink analyst Andrew Berens bumped up his target price on Mirati shares to $195 from $134 and rated the stock outperform.

Adagrasib is potentially “best-in-class,” wrote Goldman Sachs analyst Salveen Richter, who raised her price target to $267 from $152, according to Bloomberg. She thinks yearly sales of the drug could hit $3.4 billion in lung cancer either by itself or in combination with other medicines. Meanwhile, JonesTrading analysts jumped on the bandwagon, raising their target to a Wall Street high of $300.
Mizuho Securities analyst Salim Syed is less sanguine. He told clients the data “wasn’t super clean…and there are still questions that remain.”
Safety differences between the two drugs could tip the balance. The data suggest Amgen may have an edge over Mirati in terms of safety and tolerability. ” Compared to sotorasib, adagrasib had a higher rate of serious treatment-related adverse events,” analysts at SVB Leerink wrote in a note to investors.
Monday’s results are a first pass at determining whether Mirati’s therapy can perform as well as Amgen’s medication, studies of which have shown it is helpful in about half the patients who have lung cancer. However, with results from so few patients right now it’s difficult to determine which drug is more effective, according to Pasi Jänne, director of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute and paid consultant for Mirati.
“Once more patients are enrolled in the two companies’ studies, I think you can make comparisons,” said Pasi Jänne, director of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, and also a paid consultant for Mirati.
“But I think it’s encouraging that both agents are showing clinical activity for a disease where we have not had targeted therapies before,” she added.
Disclosure: The author has a position in Amgen.
Read more here:
Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.
About the author:

Barry Cohen
Barry Cohen has nearly 40 years experience in communications and marketing, the majority in senior positions at large international health care companies, including Abbott Laboratories and Bayer Inc.He has contributed to a number of financial websites, writing primarily about the stocks of health care companies.

RH – Why Is No One Talking About RH Stock?

The pandemic-laden year that is 2020 will be remembered as one that accelerated technological shifts such as e-commerce, working from home, and cord-cutting. While investors’ minds are fixated on high-flying tech stocks with outrageous valuations, RH (NYSE:RH), the high-end furniture supplier formerly known as Restoration Hardware, is up 79% this year.You would think a company with the stamp of approval from Warren Buffett’s Berkshire Hathaway would be the talk of Wall Street, but it isn’t. In addition to being a mid-cap stock, there are a couple reasons I believe RH goes under the radar.
Selling furniture is boring
Few things make people yawn more than having to buy furniture, but this is RH’s bread and butter. The company sells home furnishings, including furniture, lighting, textiles, and outdoor and garden products. I know this doesn’t get the heart racing as much as videoconferencing or connected home fitness equipment does, but the numbers last quarter were impressive.
Image source: Getty Images.

In the second quarter of 2020, RH achieved a record adjusted operating margin of 21.8% on revenue of $709.3 million. This kind of margin from a furniture shop is jaw dropping, and instead resembles metrics a luxury designer might have. LVMH Moet Hennessy Louis Vuitton, the French fashion house, had an operating margin of 21.4% in 2019.
RH Chairman and CEO Gary Friedman wants the company to do more than sell furniture. He sees RH as a $20 billion global luxury and lifestyle brand that will eventually attack the larger hospitality and housing industries. The recent success of RH, coupled with the fact that it is still very early in its growth trajectory, should warrant much more chatter.
Transforming a boring, commoditized business like furniture merchandising into a high-margin, differentiated, lifestyle brand is exciting, as RH’s stock performance year to date shows.
Isn’t retail dead?
Another key reason RH isn’t being talked about much is because it’s in the retail sector. While the financial media (rightfully) focuses on the countless closures happening this year, core to RH’s growth strategy is to open more locations. Its Design Galleries, which average 33,000 square feet in size, are necessary for RH to “climb the luxury mountain,” as Friedman says. He dislikes a digital-only strategy, and believes that RH’s desire to sell entire collections instead of individual pieces of furniture requires an immersive, in-person experience that can’t happen solely online.
Friedman emphasized this point in the Q2 shareholder letter: “In our industry, even digital native brands, the ones who have made it, have all done so by opening retail stores. Retailers who claim they make more money online than they do in their retail stores are most likely not allocating their costs by channel correctly, and to the ones who believe that their website traffic would not be negatively impacted if they closed their stores, well good luck with that strategy.”
As it continues to be overshadowed by the ongoing retail apocalypse, RH will keep going against conventional wisdom and expanding its physical footprint.

These are the best opportunities
The biggest winners for stock market investors oftentimes are the companies that were purchased when no one paid attention to them. RH’s stock has outperformed the market since its IPO in 2012, and yet it still flies under the radar primarily because of the industry it operates in. Management has ambitious plans to build a vast international brand. Investors need to buy the stock now before it’s too late.